Share

November 2023; 10 (6) Research ArticleOpen Access

SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19

Zachary S. Orban, Lavanya Visvabharathy, Gina S. Perez Giraldo, Millenia Jimenez, Igor J. Koralnik
First published August 23, 2023, DOI: https://doi.org/10.1212/NXI.0000000000200159
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
442

Share

Article Information

vol. 10 no. 6 e200159
DOI: 
https://doi.org/10.1212/NXI.0000000000200159
PubMed: 
37612134
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 4, 2023
  • Accepted in final form June 28, 2023
  • First Published August 23, 2023.
Copyright & Usage: 
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Zachary S. Orban, BS,
    2. Lavanya Visvabharathy, PhD,
    3. Gina S. Perez Giraldo, MD,
    4. Millenia Jimenez, BS and
    5. Igor J. Koralnik, MD
  1. Zachary S. Orban, BS,
    2. Scientific Advisory Boards:

    1. (1) Alexion(2) Argenx

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Abbvie(2) Alexion(3) ArgenX(4) Biogen(5) Merck(6) Novartis(7) Roche(8) Sanofi

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie(2) Alexion(3) Adivo(4) Argenx(5) Biogen(6) Merck(7) Novartis(8) Roche(9) Takeda

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Argenx(2) Biogen(3) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr Lünemann received grant support from the Swiss National Science Foundation (31003A-169664), the Sassella Foundation, the Hartmann Müller Foundation, the Olga Mayenfisch Foundation and the Swiss Multiple Sclerosis Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lavanya Visvabharathy, PhD,
    3. Scientific Advisory Boards:

    1. EUSA Pharma, Boehringer-Ingelheim

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Gina S. Perez Giraldo, MD,
    4. Scientific Advisory Boards:

    1. (1) Alexion(2) Argenx

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Abbvie(2) Alexion(3) ArgenX(4) Biogen(5) Merck(6) Novartis(7) Roche(8) Sanofi

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie(2) Alexion(3) Adivo(4) Argenx(5) Biogen(6) Merck(7) Novartis(8) Roche(9) Takeda

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Argenx(2) Biogen(3) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr Lünemann received grant support from the Swiss National Science Foundation (31003A-169664), the Sassella Foundation, the Hartmann Müller Foundation, the Olga Mayenfisch Foundation and the Swiss Multiple Sclerosis Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Millenia Jimenez, BS and
    5. Scientific Advisory Boards:

    1. (1) Alexion(2) Argenx

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Abbvie(2) Alexion(3) ArgenX(4) Biogen(5) Merck(6) Novartis(7) Roche(8) Sanofi

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie(2) Alexion(3) Adivo(4) Argenx(5) Biogen(6) Merck(7) Novartis(8) Roche(9) Takeda

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Argenx(2) Biogen(3) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr Lünemann received grant support from the Swiss National Science Foundation (31003A-169664), the Sassella Foundation, the Hartmann Müller Foundation, the Olga Mayenfisch Foundation and the Swiss Multiple Sclerosis Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Igor J. Koralnik, MD
    6. Scientific Advisory Boards:

    1. (1) Alexion(2) Argenx

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Abbvie(2) Alexion(3) ArgenX(4) Biogen(5) Merck(6) Novartis(7) Roche(8) Sanofi

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie(2) Alexion(3) Adivo(4) Argenx(5) Biogen(6) Merck(7) Novartis(8) Roche(9) Takeda

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Argenx(2) Biogen(3) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr Lünemann received grant support from the Swiss National Science Foundation (31003A-169664), the Sassella Foundation, the Hartmann Müller Foundation, the Olga Mayenfisch Foundation and the Swiss Multiple Sclerosis Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
  1. Correspondence
    Dr. Koralnik igor.koralnik{at}northwestern.edu
View Full Text

Article usage

Article usage: August 2023 to August 2023

AbstractFullPdfSource
Aug 2023105842442Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me